146 related articles for article (PubMed ID: 20598285)
1. ProCGlobal and endogenous thrombin potential during pregnancy.
Hron G; Kyrle PA; Kaider A; Philipp K; Pabinger I; Kollars M; Eichinger S
Am J Obstet Gynecol; 2010 Nov; 203(5):463.e1-6. PubMed ID: 20598285
[TBL] [Abstract][Full Text] [Related]
2. The effect of dalteparin on coagulation activation during pregnancy in women with thrombophilia. A randomized trial.
Abou-Nassar K; Kovacs MJ; Kahn SR; Wells P; Doucette S; Ramsay T; Clement AM; Khurana R; Mackinnon K; Blostein M; Solymoss S; Kingdom J; Sermer M; Rey E; Rodger M;
Thromb Haemost; 2007 Jul; 98(1):163-71. PubMed ID: 17598009
[TBL] [Abstract][Full Text] [Related]
3. Coagulation activation markers do not correlate with the clinical risk of thrombosis in pregnant women.
Bombeli T; Raddatz-Mueller P; Fehr J
Am J Obstet Gynecol; 2001 Feb; 184(3):382-9. PubMed ID: 11228491
[TBL] [Abstract][Full Text] [Related]
4. Prospective evaluation of hemostatic system activation and thrombin potential in healthy pregnant women with and without factor V Leiden.
Eichinger S; Weltermann A; Philipp K; Hafner E; Kaider A; Kittl EM; Brenner B; Mannhalter C; Lechner K; Kyrle PA
Thromb Haemost; 1999 Oct; 82(4):1232-6. PubMed ID: 10544904
[TBL] [Abstract][Full Text] [Related]
5. Prophylaxis and treatment of thrombophilia in pregnancy.
Gris JC; Lissalde-Lavigne G; Quéré I; Dauzat M; Marès P
Curr Opin Hematol; 2006 Sep; 13(5):376-81. PubMed ID: 16888444
[TBL] [Abstract][Full Text] [Related]
6. [Thrombophilia, anticoagulant therapy and pregnancy].
Boda Z; László P; Pfliegler G; Tornai I; Rejtö L; Schlammadinger A
Orv Hetil; 1998 Dec; 139(52):3113-6. PubMed ID: 9914731
[TBL] [Abstract][Full Text] [Related]
7. Assessment and management of high-risk pregnancies in women with thrombophilia.
Sarig G; Vidergor G; Brenner B
Blood Rev; 2009 Jul; 23(4):143-7. PubMed ID: 19135285
[TBL] [Abstract][Full Text] [Related]
8. Women with unexplained recurrent pregnancy loss do not have evidence of an underlying prothrombotic state: experience with calibrated automated thrombography and rotational thromboelastometry.
Bennett SA; Bagot CN; Appiah A; Johns J; Ross J; Roberts LN; Patel RK; Arya R
Thromb Res; 2014 May; 133(5):892-9. PubMed ID: 24613698
[TBL] [Abstract][Full Text] [Related]
9. The impact of dalteparin (Fragmin) on thrombin generation in pregnant women with venous thromboembolism: significance of the factor V Leiden mutation.
Schambeck CM; Eberl E; Geisen U; Grossmann R; Keller F
Thromb Haemost; 2001 May; 85(5):782-6. PubMed ID: 11372668
[TBL] [Abstract][Full Text] [Related]
10. Thrombin generation and low-molecular-weight heparin prophylaxis in pregnant women with thrombophilia.
Selmeczi A; Roach RE; Móré C; Batta Z; Hársfalvi J; van der Bom JG; Boda Z; Oláh Z
Thromb Haemost; 2015 Feb; 113(2):283-9. PubMed ID: 25392852
[TBL] [Abstract][Full Text] [Related]
11. Successful pregnancy outcome in women with bad obstetric history and recurrent fetal loss due to thrombophilia: effect of unfractionated heparin and low-molecular weight heparin.
Ghosh K; Shetty S; Vora S; Salvi V
Clin Appl Thromb Hemost; 2008 Apr; 14(2):174-9. PubMed ID: 18160603
[TBL] [Abstract][Full Text] [Related]
12. Thrombogenesis in Thrombophilic Pregnancy: Evaluation of Low-Molecular-Weight Heparin Prophylaxis.
Simeone R; Giacomello R; Bruno G; Parco S; Maximova N; Martinelli M; Zito G; Luppi S; Cervi G; Ricci G
Acta Haematol; 2017; 137(4):201-206. PubMed ID: 28478442
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulant therapy and thromboprophylaxis in patients with thrombophilia.
Weintraub AY; Sheiner E
Arch Gynecol Obstet; 2007 Dec; 276(6):567-71. PubMed ID: 17828548
[TBL] [Abstract][Full Text] [Related]
14. The procoagulant effects of factor V Leiden may be balanced against decreased levels of factor V and do not reflect in vivo thrombin formation in newborns.
Hyytiäinen S; Wartiovaara-Kautto U; Ulander VM; Kaaja R; Heikinheimo M; Petäjä J
Thromb Haemost; 2006 Mar; 95(3):434-40. PubMed ID: 16525570
[TBL] [Abstract][Full Text] [Related]
15. [Low-molecular weight heparin in the treatment of pregnant women with high thrombotic risk].
Todorova K; Mazneĭkova V; Ivanov S
Akush Ginekol (Sofiia); 2004; 43(4):46-52. PubMed ID: 15318544
[No Abstract] [Full Text] [Related]
16. [Activated protein C resistance syndrome].
Souto JC; Fontcuberta J
Sangre (Barc); 1997 Dec; 42(6):453-66. PubMed ID: 9490910
[No Abstract] [Full Text] [Related]
17. Reduction of high fetal loss rate by anticoagulant treatment during pregnancy in antithrombin, protein C or protein S deficient women.
Folkeringa N; Brouwer JL; Korteweg FJ; Veeger NJ; Erwich JJ; Holm JP; van der Meer J
Br J Haematol; 2007 Feb; 136(4):656-61. PubMed ID: 17223916
[TBL] [Abstract][Full Text] [Related]
18. Modulation of systemic hemostatic parameters by enoxaparin during gestation in women with thrombophilia and pregnancy loss.
Sarig G; Blumenfeld Z; Leiba R; Lanir N; Brenner B
Thromb Haemost; 2005 Nov; 94(5):980-5. PubMed ID: 16363240
[TBL] [Abstract][Full Text] [Related]
19. The management of thrombosis in pregnancy: role of low-molecular-weight heparin.
Kher A; Bauersachs R; Nielsen JD
Thromb Haemost; 2007 Apr; 97(4):505-13. PubMed ID: 17393011
[TBL] [Abstract][Full Text] [Related]
20. Thrombosis, thrombophilia, and thromboprophylaxis in pregnancy.
James AH; Brancazio LR; Ortel TL
Clin Adv Hematol Oncol; 2005 Mar; 3(3):187-97. PubMed ID: 16166990
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
